Summary
ST 1059, the pharmacologically active metabolite of midodrine, is a powerful vasoconstrictor compound, acting by stimulation of alpha-receptors. It elicited 80% of noradrenaline-induced contraction of human veins.
This is a preview of subscription content, log in via an institution to check access.
References
Kratz, H.: Treatment of hypotensive circulatory dysregulation in practice with Gutron. Wien. Med. Wochenschr.125, 189–192 (1975)
Lachner, O., Lillie, Ch., Rot, A.: The Pharmacological Properties of Midodrine and its Clinical Application in Patients with Hypotensive Circulatory Disturbance. Wien. Klin. Wochenschr.86, 344–348 (1974)
Pittner, H., Stormann, H., Enzenhofer, R.: Pharmacodynamic actions of Midodrine, a new alpha-adrenergic stimulating agens, and its main metabolite, ST 1059. Drug Res.26, 2145–2154 (1976)
Thulesius, O.: Pathophysiological classification and diagnosis of orthostatic hypotension. Cardiology61, Suppl. 1, 180–190 (1976)
Thulesius, O., Boe, J., Berlin, E.: Physiological and pharmacological studies on isolated human bronchial preparations. Scand. J. Respir. Dis.59, 66 (1978)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thulesius, O., Gjöres, J.E. & Berlin, E. Vasoconstrictor effect of midodrine, ST 1059, noradrenaline, etilefrine and dihydroergotamine on isolated human veins. Eur J Clin Pharmacol 16, 423–424 (1979). https://doi.org/10.1007/BF00568204
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00568204